Timing of first pembrolizumab infusion and long-term outcomes in non-small cell lung cancer: A retrospective multicenter study.

Background: Circadian rhythms modulate immunity, and a preclinical study suggests that the timing of the first immune checkpoint inhibitor dose affects antitumor efficacy. However, clinical confirmation is scarce. We aimed to evaluate whether the timing of the first pembrolizumab infusion affects outcomes in unresectable non-small cell lung cancer (NSCLC).

Case of a rare EGFR mutation L identified using the lung cancer compact Panel™ leading to successful Afatinib treatment.

This report describes the case of a 44-year-old Japanese female diagnosed with Stage IA lung adenocarcinoma harboring a rare epidermal growth factor receptor () mutation. Conventional polymerase chain reaction (PCR)-based assays did not identify the mutation. Despite undergoing surgery and subsequent chemoradiotherapy, disease recurrence occurred.

Real-world Data of the Lung Cancer Compact Panel™ in Non-small Cell Lung Cancer Using Tissue Samples.

Background/aim: Multiple companion diagnostics are essential for detecting genetic alterations and guiding personalized treatment in patients with non-small cell lung cancer (NSCLC). The Lung Cancer Compact Panel™ (LCCP) is a newly developed multiple companion diagnostic tool designed to detect genetic mutations in NSCLC with high sensitivity, compatible with tissue and cytological samples. There has been no large-scale validation of the LCCP that includes tissue samples.

Real-World Efficacy and Safety of Lenvatinib in Advanced or Recurrent Thymic Carcinoma: A Multicenter Retrospective Study in Japan.

Background: Lenvatinib is recommended for the treatment of advanced and recurrent thymic carcinomas. However, there is a paucity of data on lenvatinib's use in real-world clinical practice. The aim of this study was to evaluate the efficacy and safety of lenvatinib in patients with thymic carcinoma.

Safety and Efficacy of Durvalumab After Chemoradiotherapy in Antinuclear Antibody-positive Patients With Non-small Cell Lung Cancer.

Background/aim: Pneumonitis during durvalumab consolidation therapy after chemoradiotherapy (CRT) is a major cause of treatment discontinuation. Although previous studies have revealed an association between antinuclear antibody (ANA) positivity and the safety and efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC), there are no reports on durvalumab consolidation therapy. This study investigated the safety and efficacy of durvalumab after CRT in ANA-positive patients.

Concurrent Nivolumab-Induced Gastritis and Cholangitis Accompanied by Biliary Tract Hemorrhage in a Patient With Stage IV Lung Adenocarcinoma.

Immune checkpoint inhibitors, including nivolumab, can result in immune-related adverse events (irAEs) that may affect multiple organ systems. Among irAEs, both gastritis and cholangitis are uncommon. We present the case of a 65-year-old man who received nivolumab for lung adenocarcinoma presented with epigastric pain.

Lenvatinib-refractory thymic mucinous carcinoma with mutation.

Mucinous adenocarcinoma, a very rare type of thymic carcinoma, is aggressive and has a poor prognosis. The optimal treatment for advanced thymic mucinous adenocarcinoma has not yet been established because of its rarity. An oral multi-tyrosine kinase inhibitor, lenvatinib, was approved for treatment of thymic carcinoma in March 2021 in Japan.

Successful Dasatinib Treatment of Epidermal Growth Factor Receptor-Mutant Lung Adenocarcinoma and -Positive Chronic Myeloid Leukemia: A Case Report.

Dasatinib, a second-generation tyrosine kinase inhibitor (TKI), inhibits multiple kinase pathways and is a promising anti-tumor agent for various solid tumors, including lung cancer. Herein, we report a patient with coexisting epidermal growth factor receptor ()-mutant lung adenocarcinoma and -positive chronic myeloid leukemia (CML). The patient received afatinib for a postoperative intrapulmonary recurrence of lung adenocarcinoma harboring exon 19 deletion.